NewAmsterdam Pharma Number Of Shares Shorted vs. Net Income
| NAMS Stock | 20.20 0.08 0.40% |
For NewAmsterdam Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NewAmsterdam Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NewAmsterdam Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NewAmsterdam Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NewAmsterdam Pharma over time as well as its relative position and ranking within its peers.
NewAmsterdam |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewAmsterdam Pharma. If investors know NewAmsterdam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewAmsterdam Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.21) | Revenue Per Share 0.373 | Quarterly Revenue Growth 8.898 | Return On Assets (0.29) | Return On Equity (0.47) |
The market value of NewAmsterdam Pharma is measured differently than its book value, which is the value of NewAmsterdam that is recorded on the company's balance sheet. Investors also form their own opinion of NewAmsterdam Pharma's value that differs from its market value or its book value, called intrinsic value, which is NewAmsterdam Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewAmsterdam Pharma's market value can be influenced by many factors that don't directly affect NewAmsterdam Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NewAmsterdam Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if NewAmsterdam Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewAmsterdam Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
NewAmsterdam Pharma Net Income vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NewAmsterdam Pharma's current stock value. Our valuation model uses many indicators to compare NewAmsterdam Pharma value to that of its competitors to determine the firm's financial worth. NewAmsterdam Pharma is rated below average in number of shares shorted category among its peers. It is rated below average in net income category among its peers . At this time, NewAmsterdam Pharma's Net Loss is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value NewAmsterdam Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.NewAmsterdam Net Income vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
NewAmsterdam Pharma |
| = | 718.04 K |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
NewAmsterdam Pharma |
| = | (160.27 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
NewAmsterdam Net Income Comparison
NewAmsterdam Pharma is currently under evaluation in net income category among its peers.
NewAmsterdam Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NewAmsterdam Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NewAmsterdam Pharma will eventually generate negative long term returns. The profitability progress is the general direction of NewAmsterdam Pharma's change in net profit over the period of time. It can combine multiple indicators of NewAmsterdam Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 4.4 M | 3.6 M | |
| Net Interest Income | 3.4 M | 3.6 M | |
| Interest Income | 11.3 M | 11.8 M | |
| Operating Income | -165.7 M | -157.4 M | |
| Net Loss | -176.9 M | -168.1 M | |
| Income Before Tax | -160.2 M | -152.2 M | |
| Total Other Income Expense Net | 5.5 M | 5.8 M | |
| Net Loss | -25.7 M | -27 M | |
| Net Loss | -160.3 M | -152.3 M | |
| Income Tax Expense | 27 K | 25.6 K | |
| Change To Netincome | -360.9 K | -342.9 K | |
| Net Loss | (2.15) | (2.26) | |
| Income Quality | 0.88 | 0.74 | |
| Net Income Per E B T | 0.99 | 0.88 |
NewAmsterdam Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NewAmsterdam Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NewAmsterdam Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NewAmsterdam Pharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in NewAmsterdam Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Commodity Directory Now
Commodity DirectoryFind actively traded commodities issued by global exchanges |
| All Next | Launch Module |
Use Investing Themes to Complement your NewAmsterdam Pharma position
In addition to having NewAmsterdam Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Biotech Thematic Idea Now
Biotech
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.